AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18433945
Drug: Glutamate ingestion
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate ingestion (30 mg/kg BW)
Trial: 18433945
Drug: Control ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control ingestion (1.25 ml/kg BW)
Trial: 10718783
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg once daily for 8 days
Trial: 3886340
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg orally each morning)
Trial: 3886340
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg orally twice daily)
Trial: 22057829
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) 10 ppm followed by sildenafil 100 mg orally 30 minutes later
Trial: 22057829
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg orally followed by inhaled nitric oxide (iNO) 10 ppm 60 minutes later
Trial: 19821509
Drug: Teduglutide 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide 0.2 mg/kg daily
Trial: 19821509
Drug: Teduglutide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide 0.1 mg/kg daily
Trial: 19821509
Drug: Teduglutide 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide 0.05 mg/kg daily
Trial: 19821509
Drug: Teduglutide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide 0.1 mg/kg daily (open-label phase)
Trial: 19821509
Drug: Teduglutide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide (all doses)
Trial: 17432690
Drug: Compound Shiwei
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Shiwei Tablet (CST)
Trial: 17432690
Drug: Sanjin Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanjin Tablet (ST)
Trial: 15367305
Drug: Pamidronate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (60 mg as a single dose)
Trial: 8996853
Drug: Pellet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pellet formulation (R)
Trial: 28644104
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg every 8 weeks (first three doses every 4 weeks)
Trial: 26148133
Drug: Low-dose creatine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose creatine supplementation (acute and chronic)
Trial: 26148133
Drug: High-dose creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose creatine supplementation (acute and chronic)
Trial: 25098088
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of injection Celfuroxime 1.5 gm at the time of induction of anaesthesia (Group A)
Trial: 25098088
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (Group B)
Trial: 19092349
Drug: Methylprednisolone treatment
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone treatment (250 mg at consent, followed by 100 mg/h infusion)
Trial: 17159174
Drug: Indometacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (75 mg) sustained release once daily for six weeks
Trial: 17159174
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for six weeks
Trial: 7054760
Drug: Hydrocortisone hemisuccinate,
RxNorm normalized name: Hydrocortisone Hemisuccinate, hemisuccinate compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone hemisuccinate, 50 mg/kg body weight
Trial: 29052033
Drug: Perturbation-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perturbation-based therapy (random-perturbation exercise, 13 weeks, 2 times per week, 1.5 hours per session)
Trial: 21237718
Drug: Triple antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiretroviral prophylaxis (300 mg zidovudine, 150 mg lamivudine, and 400 mg lopinavir plus 100 mg ritonavir twice daily until cessation of breastfeeding, maximum 6.5 months postpartum)
Trial: 21237718
Drug: Zidovudine and
RxNorm normalized name: zidovudine and lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine and single-dose nevirapine (300 mg zidovudine twice daily until delivery, 600 mg zidovudine plus 200 mg nevirapine at onset of labour, and after protocol amendment, 300 mg zidovudine twice daily and 150 mg lamivudine twice daily for 1 week postpartum)
Trial: 19373709
Drug: Psychoanalytic psychotherapy
RxNorm normalized name: PSYCHOANALEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytic psychotherapy (once‐ or twice‐weekly for 4‐12 months)
Trial: 17766660
Drug: Docetaxel (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (single agent)
Trial: 11432768
Drug: Micronutrient and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient and single cell oil supplement containing docosahexaenoic acid
Trial: 7996818
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment with artificial tears
Trial: 21359920
Drug: Electro-acupuncture combined
RxNorm normalized name: combinations of electrolytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture combined with Fluoxetine
Trial: 21359920
Drug: Fluoxetine only
RxNorm normalized name: Fluoxetine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine only (Control)
Trial: 21191332
Drug: Splat Oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Splat Oral Care Foam 2 in 1
Trial: 17701405
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg PO omeprazole (young subjects)
Trial: 17701405
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg IV omeprazole (young subjects)
Trial: 17701405
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg IV omeprazole (elderly subjects)
Trial: 16393158
Drug: Pregabalin flexible
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin flexible dose (150 and 300 mg/day for 2 weeks each; 450 and 600 mg/day for 4 weeks each, BID)
Trial: 16393158
Drug: Pregabalin fixed
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin fixed dose (600 mg/day BID)
Trial: 16393158
Drug: Pregabalin fixed
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin fixed dose vs flexible dose
Trial: 16393158
Drug: Pregabalin flexible
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin flexible dose
Trial: 16393158
Drug: Pregabalin fixed
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin fixed dose
Trial: 8653534
Drug: Orlistat 360
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 360 mg per day
Trial: 220536
Drug: Interferon (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (administered for six weeks starting on the day of transplantation)
Trial: 27702806
Drug: 1.25% fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25% fluoride gel application
Trial: 21536191
Drug: Heavy rotational
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy rotational force (225 g)
Trial: 21536191
Drug: Light rotational
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light rotational force (25 g)
Trial: 21536191
Drug: Compression areas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression areas (buccal‐distal and lingual‐mesial surfaces)
Trial: 15663094
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (CDDP+FU, TAX+FU, CDDP)
Trial: 15663094
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment only (Control group)
Trial: 3111702
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3 mg dihydroergocristine and 100 mg levo‐5‐hydroxytryptophan
Trial: 27498100
Drug: Bilastine 50
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Bilastine 50 mg
Trial: 15220247
Drug: Fixed-dose trandolapril-verapamil
RxNorm normalized name: trandolapril / verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose trandolapril-verapamil (FDTV) 2 mg trandolapril/180 mg verapamil once daily
Trial: 15220247
Drug: Fixed-dose trandolapril-verapamil
RxNorm normalized name: trandolapril / verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose trandolapril-verapamil (FDTV)
Trial: 2802896
Drug: Aspartame (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (75 mg/kg per day, capsule form, three times daily for 24 weeks)
Trial: 2802896
Drug: Placebo (capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (capsule form, three times daily for 24 weeks)
Trial: 31546498
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: Low parameters (AFR = 20 cc/min, BH = 90 cm, vacuum = 400 mmHg)
Trial: 31546498
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: High parameters (AFR = 40 cc/min, BH = 110 cm, vacuum = 650 mmHg)
Trial: 28599034
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) treatment, moleskin and Tegaderm®
Trial: 28202770
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) treatment
Trial: 16490895
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing (sugarless gum 3 times daily for 1 hour each until discharge)
Trial: 11323373
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume breathing (TVB) for 3-5 min at 5, 7, and 10 L/min fresh gas flow (FGF)
Trial: 11323373
Drug: Four deep
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four deep breaths (DB) in 0.5 min at 5, 7, and 10 L/min FGF
Trial: 11323373
Drug: Eight deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight deep breaths (DB) in 1 min at 7 and 10 L/min FGF
Trial: 11323373
Drug: Deep breathing
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep breathing extended to 1.5 and 2 min with 10 L/min FGF
Trial: 11323373
Drug: Increasing FGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing FGF from 5 to 10 L/min
Trial: 29393208
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone dose adjustments to reach plasma R-methadone levels (80-250 ng/mL)
Trial: 20795751
Drug: Menveo vaccine
RxNorm normalized name: Menveo Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menveo vaccine
Trial: 16881934
Drug: Prolonged thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged thromboprophylaxis with dalteparin (5000 IU once daily for 28 days)
Trial: 12832673
Drug: gemifloxacin 320
RxNorm normalized name: gemifloxacin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemifloxacin 320 mg once daily for 5 days
Trial: 12832673
Drug: clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clarithromycin 500 mg twice daily for 7 days
Trial: 9072891
Drug: Application of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of antioxidants in combined treatment of schizophrenic patients
Trial: 3921278
Drug: Diltiazem (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (up to 360 mg daily)
Trial: 3921278
Drug: Propranolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol plus maximum tolerated dose of diltiazem
Trial: 26726854
Drug: Brief positive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief positive psychotherapy plus usual treatment
Trial: 22795046
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy coupled with cognitive behavioral therapy (MET‐CBT)
Trial: 9266876
Drug: Cefuroxime, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime, 1.5 g IV tid for 48 to 72 h followed by oral cefuroxime axetil, 500 mg bid for 7 days
Trial: 9266876
Drug: Cefuroxime, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime, 1.5 g IV bid for 48 to 72 h followed by oral cefuroxime axetil, 500 mg bid for 7 days
Trial: 8302152
Drug: Continuous succinylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous succinylcholine infusion
Trial: 8302152
Drug: Single-dose technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose technique
Trial: 22889466
Drug: Intra-umbilical injection
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-umbilical injection of oxytocin (50 IU diluted with normal saline to a total volume of 30 mL)
Trial: 22889466
Drug: Intra-umbilical injection
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-umbilical injection of normal saline (30 mL)
Trial: 21277062
Drug: midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam and 1‐mg/kg tramadol
Trial: 21277062
Drug: midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam and 1‐μg/kg fentanyl
Trial: 19843062
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (education on disease state, medications, and breathing techniques)
Trial: 16488953
Drug: NSAID ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID ophthalmic solution (sodium 2‐amino‐3‐(4‐bromobenzoyl) phenylacetate sesquihydrate) administered for 12 weeks
Trial: 16488953
Drug: Sodium hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronic acid ophthalmic solution (control group) administered for 12 weeks
Trial: 11128921
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (GP-)
Trial: 9304635
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of oral ketorolac tromethamine (KT) 2 hours prior to surgery
Trial: 9304635
Drug: 0.03% flurbiprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% flurbiprofen sodium (FS) topical solution
Trial: 9304635
Drug: Topical normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical normal saline
Trial: 8141723
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of heparin
Trial: 3087694
Drug: Norplant (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norplant (six capsules)
Trial: 30626347
Drug: Thrice-weekly hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly hemodialysis regimen
Trial: 24490949
Drug: Ginger (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (1600 mg daily for 12 weeks)
Trial: 24490949
Drug: Placebo (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1600 mg wheat flour daily for 12 weeks)
Trial: 16198982
Drug: 5-HT-receptor antagonists
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT-receptor antagonists (standard dose, IV/oral)
Trial: 9589243
Drug: Troglitazone 400
RxNorm normalized name: troglitazone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 400 mg daily for 8 weeks
Trial: 7998769
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange (twice a week for 3 weeks then once a week for 3 weeks)
Trial: 7998769
Drug: Immune globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune globulin infusion (0.4 gm/kg once a week for 3 weeks, then 0.2 gm/kg once a week for the next 3 weeks)
Trial: 7998769
Drug: Immune globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune globulin infusion
Trial: 2897788
Drug: Glutamic acid
RxNorm normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamic acid 500 mg orally three times daily plus vincristine 1.0 mg/m2 weekly for six doses
Trial: 2897788
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus vincristine 1.0 mg/m2 weekly for six doses
Trial: 29017421
Drug: Comprehensive medication
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive medication reviews (CMRs) by intervention pharmacists
Trial: 26927249
Drug: Low-dose add-back
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose add-back therapy (estradiol valerate 1 mg and medroxyprogesterone acetate 2.5 mg, once a day)
Trial: 26927249
Drug: Regular-dose add-back
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular-dose add-back therapy (estradiol valerate 1 mg and medroxyprogesterone acetate 2.5 mg, twice a day)
Trial: 26927249
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (low dose and regular dose)
Trial: 24690416
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Atomoxetine (ATX)
Trial: 24690416
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 10 Hz rTMS and 60 mg ATX
Trial: 16211736
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg and paracetamol 1.5 g
Trial: 16211736
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and paracetamol 1.5 g
Trial: 8658044
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (21/min by nasal prongs)
Trial: 8658044
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oxygen therapy)
Trial: 1610863
Drug: Double-drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-drug therapy (cyclosporine and azathioprine)
Trial: 1610863
Drug: Double-drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-drug therapy
Trial: 6734370
Drug: Diltiazem 90
RxNorm normalized name: diltiazem 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 90 mg QID
Trial: 6734370
Drug: Diltiazem (90,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90, 120, 150 mg)
Trial: 24626733
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with 14 mL of 0.75% ropivacaine plus 4.0 mcg/kg of clonidine
Trial: 24626733
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with 14 mL of ropivacaine 0.75 % plus 0.0266 mL/kg of 0.9% saline solution
Trial: 23092451
Drug: Weekly supplementation
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supplementation of 2800 μg folic acid
Trial: 23092451
Drug: Weekly supplementation
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supplementation of 60 mg iron and 2800 μg folic acid
Trial: 23092451
Drug: Weekly supplementation
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supplementation of multiple micronutrients (MM)
Trial: 21053992
Drug: Linagliptin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 0.5 mg intravenously
Trial: 21053992
Drug: Linagliptin 2.5
RxNorm normalized name: linagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 2.5 mg intravenously
Trial: 21053992
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg intravenously and 10 mg oral tablet (crossover)
Trial: 21053992
Drug: Linagliptin 10
RxNorm normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 10 mg intravenously